ANWA Stock Chart & Stats
€0.95
€0.04(4.28%)
At close: 4:00 PM EDT
€0.95
€0.04(4.28%)
Day’s Range― - ―
52-Week Range€0.49 - €2.08
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.61M
Enterprise Value-€1.44
Total Cash (Recent Filing)€9.02M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding8,071,202
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.04
Price to Sales (P/S)1.51
P/FCF Ratio-3.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€5.55M
Bulls Say, Bears Say
Bulls Say
Commercial Traction And Gross MarginRevenue expansion over several years shows that Immuron has converted its gastrointestinal platform into a commercial business. The solid gross margin indicates product economics can support further growth, although operating expenses and development spending still need to be covered.
Debt-free Balance SheetHaving no debt reduces refinancing exposure, interest obligations, and financial pressure while the company funds commercial products and clinical programs. Its equity and asset base provide a cushion against volatility, preserving flexibility for future operating and development decisions.
Focused Gastrointestinal PlatformThe company combines marketed gastrointestinal health products with clinical-stage therapeutics built on a common antibody platform. This creates multiple avenues for product development and commercialization across gut-related conditions, rather than relying on a single early-stage candidate.
Bears Say
Revenue VolatilityThe latest revenue contraction shows that commercialization has not yet produced a consistently expanding sales base. Continued volatility could limit operating leverage, make planning more difficult, and delay the point at which the company can cover research, development, and corporate costs.
Persistent Operating LossesImmuron remains materially unprofitable even after revenue scaled and gross margin reached about 64%. The continuing operating deficit indicates that current product contribution is insufficient to fund the broader business, leaving profitability dependent on stronger sales or lower spending.
Negative Cash GenerationOngoing negative operating and free cash flow means the business is not currently self-funding. Although cash burn improved from 2025, continued outflows can consume the capital base and may require additional funding if commercial growth and clinical progress do not improve sufficiently.
Immuron News
ANWA FAQ
What was Immuron Ltd’s price range in the past 12 months?
Immuron Ltd lowest stock price was €0.49 and its highest was €2.08 in the past 12 months.
What is Immuron Ltd’s market cap?
Immuron Ltd’s market cap is €9.61M.
When is Immuron Ltd’s upcoming earnings report date?
Immuron Ltd’s upcoming earnings report date is Feb 19, 2027 which is in 149 days.
How were Immuron Ltd’s earnings last quarter?
Immuron Ltd released its earnings results on Aug 27, 2026. The company reported -€0.143 earnings per share for the quarter, missing the consensus estimate of -€0.003 by -€0.14.
Is Immuron Ltd overvalued?
According to Wall Street analysts Immuron Ltd’s price is currently Overvalued.
Does Immuron Ltd pay dividends?
Immuron Ltd does not currently pay dividends.
What is Immuron Ltd’s EPS estimate?
Immuron Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immuron Ltd have?
Immuron Ltd has 8,071,202 shares outstanding.
What happened to Immuron Ltd’s price movement after its last earnings report?
Immuron Ltd reported an EPS of -€0.143 in its last earnings report, missing expectations of -€0.003. Following the earnings report the stock price went up 2.151%.
Which hedge fund is a major shareholder of Immuron Ltd?
Currently, no hedge funds are holding shares in DE:ANWA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immuron Ltd
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.